Compare Citius Pharmaceuticals Inc (CTXR) vs Prospect Capital Corporation (PSEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Prospect Capital Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.79M), while Prospect Capital Corporation trades at $1.83 (market cap $984.89M). The key difference: Prospect Capital Corporation is far larger — about 71.4× Citius Pharmaceuticals Inc's market cap, and Prospect Capital Corporation pays a 22.76% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Prospect Capital Corporation for 78 Days on average.
| CTXR | PSEC | |
|---|---|---|
Market Cap | $13.79M | $984.89M |
Volume | 156,684 | 10,087,405 |
Sector | Health | Financials |
52-Week High | $1.82 | $3.05 |
52-Week Low | $0.48 | $1.82 |
Typical Hold Time | 16 Days | 78 Days |
Enterprise Value | $3.96M | $2.74B |
Dividend Yield | — | 22.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, but remains in a bearish technical trend with negative profitability metrics. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR sales, though net income margin remains deeply negative at -651.27%. Analyst consensus is strongly bullish with 5 buy ratings and a $5.00 price target, representing significant upside potential from current levels.
While CTXR shows promising commercial progress with its oncology drug launch, the stock faces substantial execution risks due to persistent losses and cash burn. The bullish analyst sentiment contrasts with weak fundamentals, creating a high-risk, high-reward scenario for investors betting on successful commercialization of LYMPHIR in the $400M+ CTCL market.
PSEC trades at $1.84, up 0.55% with bearish technical signals despite recent earnings beats. The company shows inconsistent revenue trends with 2025 revenue at -$407M and net income of -$470M, though 2026 projections indicate recovery. Dividend payments continue at $0.04 monthly, while analyst sentiment remains mixed with 25% buy ratings amid concerns about NAV erosion and portfolio contraction.
PSEC presents high risk with volatile financial performance and bearish technical indicators. The 18%+ dividend yield appears unsustainable given negative cash flow and declining portfolio value. While current price represents a significant discount to book value, ongoing NAV erosion and mixed analyst consensus suggest cautious approach for investors seeking stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →
